Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma
Open Access
- 10 October 2013
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 6 (6), 1707-1712
- https://doi.org/10.3892/ol.2013.1612
Abstract
In this study, Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), Choi and modified Choi criteria were compared to determine which method is optimal for response evaluation in hepatocellular carcinoma (HCC) patients treated with transarterial radioembolization (TARE) with yttrium-90 microspheres. Responses were evaluated by RECIST, mRECIST, Choi and modified Choi criteria in 113 patients with HCC undergoing TARE. Results were compared at 12 weeks after therapy. Kaplan-Meier survival analyses and Cox regression were used to assess differences in time to progression (TTP) and overall survival (OS) between the responders and non-responders defined by each method. The results demonstrated that the responders and non-responders defined by mRECIST and Choi criteria successfully identified patients with a long TTP (400 and 280 days) or short TTP (188 and 166 days) (P=0.004 and 0.002, respectively). Neither RECIST nor modified Choi criteria discriminated between patients who had a short or long clinical benefit. Cox regression analysis revealed that Choi response was a prognostic factor of OS (P=0.004) and was associated with a 53% risk reduction. There was no significant association between survival and RECIST, mRECIST and modified Choi responses. In conclusion, tumor response according to Choi criteria may be helpful to define early HCC patients who benefit from TARE. RECIST, mRECIST and modified Choi appeared inferior.Keywords
This publication has 17 references indexed in Scilit:
- Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver TumorsAmerican Journal of Clinical Oncology, 2012
- Radioembolization for hepatocellular carcinomaJournal of Hepatology, 2012
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapiesCancer Biology & Therapy, 2010
- Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CTAmerican Journal of Roentgenology, 2010
- SPECT/CT with 99mTc-MAA in Radioembolization with 90Y Microspheres in Patients with Hepatocellular CancerJournal of Nuclear Medicine, 2009
- Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response CriteriaJournal of Clinical Oncology, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000